Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami

New presentations for tildrakizumab-asmn explore real-world use in U.S. patients using Medicare; New data specific to patients with skin of color expands evidence supporting strong efficacy and safety for clascosterone cream 1%

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Sun Pharmaceutical Industries Limited announced the company will share 19 abstracts, including new clinical data, across its dermatology and immunology portfolio, at 2026 Winter Clinical Miami on February 27-March 1, 2026 in Aventura, Florida. The data presentations will include study results for several medications, including ILUMYA ® (tildrakizumab-asmn), WINLEVI ® (clascosterone cream 1%) and LEQSELVI™ (deuruxolitinib).

Why it matters

The data being shared at Winter Clinical Miami reflect Sun Pharma's patient-first focus on generating robust clinical and real-world evidence for the treatment of alopecia areata, plaque psoriasis, and acne. Continued scientific evidence is essential to better inform clinical decision-making for dermatology clinicians.

The details

The ILUMYA data includes new real-world analyses examining biologic use and continuity of care in patients with moderate-to-severe plaque psoriasis, including older and clinically complex patient populations. Additional presentations evaluate real-world effectiveness and patient-reported outcomes across prior biologic experience and U.S. geographic regions. New, open-label, 52-week data from a pilot study evaluating WINLEVI in patients with skin of color demonstrated sustained improvement in acne severity with a consistent safety and tolerability profile. Pilot combination studies show that incorporating WINLEVI into multimodal acne treatment regimens provides benefit. The LEQSELVI data shows that it enables early and sustained scalp hair regrowth in severe alopecia areata, with consistent benefits across key subgroups.

  • The conference will take place on February 27-March 1, 2026 in Aventura, Florida.

The players

Sun Pharmaceutical Industries Limited

A global pharmaceutical company that develops and manufactures a wide range of pharmaceutical formulations and active pharmaceutical ingredients.

ILUMYA (tildrakizumab-asmn)

A humanized monoclonal antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

WINLEVI (clascosterone cream 1%)

A topical androgen receptor inhibitor indicated for the treatment of acne vulgaris in patients 12 years of age and older.

LEQSELVI (deuruxolitinib)

An oral selective inhibitor of Janus kinases JAK1 and JAK2 approved for the treatment of adults with severe alopecia areata.

Ahmad Naim, MD

Senior Vice President and North American Chief Medical Officer at Sun Pharma.

Got photos? Submit your photos here. ›

What they’re saying

“The data we are sharing at Winter Clinical Miami reflect our patient-first focus on generating robust clinical and real‑world evidence for the treatment of alopecia areata, plaque psoriasis, and acne. Continued scientific evidence is essential to better inform clinical decision-making for dermatology clinicians.”

— Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer, Sun Pharma (Sun Pharmaceutical Industries Limited)

The takeaway

Sun Pharma's robust data presentations at the 2026 Winter Clinical Miami conference demonstrate the company's commitment to advancing scientific understanding and improving patient outcomes in key dermatology and immunology areas like plaque psoriasis, acne, and alopecia areata.